

AMENDMENTS TO THE CLAIMS

Claims 1-84 (Canceled)

Claim 85 (Currently Amended): A method of preparing an immunogenic composition, comprising the steps of:

- (a) providing an autologous target tumor or pathogen infected cell;
- (b) treating the tumor or pathogen infected cell with ~~a cytokine~~ IFN- γ and/or TNF- α to increase concentration of a primary T cell activation molecule or a costimulatory T cell activation molecule in the target tumor or pathogen infected cell;
- (c) providing a bispecific monoclonal antibody including one or more binding sites for one or more costimulatory molecules on a surface of one or more T cells of a patient mammal;
- (d) attaching the bispecific monoclonal antibody to the target tumor or pathogen infected cell; and
- (e) collecting a pharmaceutically effective amount of the target tumor or pathogen infected cell with the attached bispecific monoclonal antibody.

Claims 86-90 (Canceled)

Claim 91 (Previously submitted): The method of claim 85, wherein an autologous target tumor cell is provided.

Claim 92 (Previously submitted): The method of claim 91, wherein the tumor cell is selected from the group consisting of a hepatocellular carcinoma cell, a lymphoma cell, a colon carcinoma cell and a gastric cancer cell.

Claim 93 (Canceled).

Claim 94 (Previously submitted): The method of claim 85, wherein the T cell is selected from the group consisting of a CD3+, a CD8+ and a CD25+ T cell.

Claim 95 (Previously submitted): The method of claim 85, wherein the costimulatory T cell activation molecule is CD28 or 4-1BB molecule.